SEC Filing Summary for ADC Therapeutics SA

This filing details a grant of 675,000 restricted stock units (RSUs) to Ameet Mallik, the Chief Executive Officer of ADC Therapeutics SA, on June 30, 2026. These RSUs are scheduled to vest on June 30, 2027, or earlier upon termination of employment under specific conditions, provided continued employment. Each RSU represents a contingent right to one share of the company's common stock. Following this grant, Mr. Mallik's post-transaction share ownership is reported to be 2,121,769 shares. The transaction is coded as an acquisition (Code A) with a transaction price of $0.00, indicating it was an award rather than a purchase.